Scancell Holdings (FRA:SCP) Gross-Profit-to-Asset % : 0.00% (As of Oct. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Scancell Holdings Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Scancell Holdings's annualized Gross Profit for the quarter that ended in Oct. 2023 was €0.00 Mil. Scancell Holdings's average Total Assets over the quarter that ended in Oct. 2023 was €30.02 Mil. Therefore, Scancell Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Oct. 2023 was 0.00%.

Scancell Holdings Gross-Profit-to-Asset % Historical Data

The historical data trend for Scancell Holdings's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Gross-Profit-to-Asset % Chart

Scancell Holdings Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

13.39

Scancell Holdings Semi-Annual Data
	Apr14	Oct14	Apr15	Oct15	Apr16	Oct16	Apr17	Oct17	Apr18	Oct18	Apr19	Oct19	Apr20	Oct20	Apr21	Oct21	Apr22	Oct22	Apr23	Oct23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	-	24.18	-	-

Competitive Comparison of Scancell Holdings's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Scancell Holdings's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scancell Holdings's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's Gross-Profit-to-Asset % falls into.

Scancell Holdings Gross-Profit-to-Asset % Calculation

Scancell Holdings's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Apr. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Apr. 2023 )	/	( (Total Assets (A: Apr. 2022 )	+	Total Assets (A: Apr. 2023 ))	/ count )
	=	5.39	/	( (46.145	+	34.379)	/ 2 )
	=	5.39	/	40.262
	=	13.39 %

Scancell Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Oct. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Oct. 2023 )	/	( (Total Assets (Q: Apr. 2023 )	+	Total Assets (Q: Oct. 2023 ))	/ count )
	=	0	/	( (34.379	+	25.667)	/ 2 )
	=	0	/	30.023
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Oct. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Scancell Holdings Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Scancell Holdings (FRA:SCP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (FRA:SCP) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

SCLP.GB:UK SCLP:UK

Address

Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD

Website

https://www.scancell.co.uk

Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (FRA:SCP) Headlines

No Headlines